International
The Morning Science

What science found today

‹
 

News

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss

Medical Xpress ·

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss

The Brief

  • GLP-1 receptor agonists have surged in popularity across the United States.
  • The drugs have moved from specialized type 2 diabetes treatments toward weight management and cardiovascular health uses.
  • Many patients who are eligible for GLP-1 weight-loss drugs are unable to access them despite the demand.

Why it matters

It shows a gap between who is clinically eligible for GLP-1 weight-loss drugs and who can actually obtain them, which matters for anyone studying obesity treatment or health policy.

Who’s affected

  • clinicians and researchers in obesity and cardiometabolic health
  • US patients who may be eligible for GLP-1 weight-loss treatment

In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other…

How do you feel about this?

0 Comments

    Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss – The Morning Science